This article is more than 5 years old. Information may no longer be current.

SSDLP for the treatment of CNV in AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT LAUDERDALE, Fla. – Researcher R.J. Olk and colleagues at The Retina Center of St. Louis presented a poster, “Subthreshold Subfoveal Diode (810 nm) Laser Photocoagulation (SSDLP) for the Treatment of Occult Choroidal Neovascularization (CNV) in Exudative Age-Related Macular Degeneration (AMD),” at the Association for Research in Vision and Ophthalmology (ARVO) meeting here.

One hundred ninety-five eyes (148 patients) with occult CNV underwent SSDLP with an 810 nm diode laser, a 2, 3 or 4.5 mm spot size, with 535, 800 or 1200 mw power for duration of 1 minute. One hundred thirty-six eyes had occult CNV only; 19 eyes had occult +<50% classical; 34 eyes were HPED; and 6 eyes had a fibrous scar with MED. Ages ranged from 52 to 94, 79 being the median age, with 66 males and 82 females involved in the study. Follow-up clinical examinations were performed at 3, 6 and 12 months, and included best-corrected visual acuity on the ETDRS chart, fundus photographs, and fluorescein and indocyanine green angiography.

At three months, of the 166 eyes examined, visual acuity had improved at least 3 lines in 16 eyes, had stabilized in 123 eyes, and worsened in 27 eyes. At the six month follow-up, of the 109 eyes examined, visual acuity had improved up to 3 lines in 16 patients, stabilized in 75 eyes, and worsened in 18 eyes. At twelve months, visual acuity had improved up to 3 lines in 3 eyes, stabilized in 20 eyes, and worsened in 6 eyes.

The researchers concluded that SSDLP decreases exudation by 79% at 6 months and by 86% at 12 months, improves/stabilizes vision by 79% at 12 months, and maintains reading/driving vision by 21% at 12 months.